Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus reduced tacrolimus vs standard tacrolimus in living donor liver transplant recipients (Japan)
jRCT2080222301Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2013
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of everolimus in liver transplant and Hepatic transplant rejection (LTR) (2 arms), sponsored by Novartis. Started Nov 2013; status: completed.
02
Drugs
everolimus
03
Conditions
liver transplantHepatic transplant rejection (LTR)
Beyond the preview
Go deeper on jRCT2080222301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222301.